Tetrabutylammonium Fluoride → HCID 178474062、化合物
反応式
[O:1]=[S:2]1(=[O:36])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[N:8]=[C:9]([C:25]2[C:30]([CH3:31])=[CH:29][N:28]=[C:27]([NH:32][C:33](=[O:35])[CH3:34])[CH:26]=2)[O:10][C:11]=1[C:12]1[N:16]=[CH:15][N:14](COCC[Si](C)(C)C)[N:13]=1.CCCC[N+](CCCC)(CCCC)CCCC.[F-]>C1COCC1>[O:36]=[S:2]1(=[O:1])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[N:8]=[C:9]([C:25]2[C:30]([CH3:31])=[CH:29][N:28]=[C:27]([NH:32][C:33](=[O:35])[CH3:34])[CH:26]=2)[O:10][C:11]=1[C:12]1[NH:16][CH:15]=[N:14][N:13]=1参加物
4
実験手順
To a solution of N-{4-[4-(1,1-dioxidoisothiazolidin-2-yl)-5-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,2,4-triazol-3-yl)-1,3-oxazol-2-yl]-5-methylpyridin-2-yl}acetamide (from the previous step) in THF (10 mL) was added TBAF in THF (1M, 3.3 mL). The reaction mixture was allowed to stir at rt overnight. The mixture was concentrated to dryness and then diluted with EtOAc. The mixture was washed with water. The organic solution was dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography to give N-{4-[4-(1,1-dioxidoisothiazolidin-2-yl)-5-(4H-1,2,4-triazol-3-yl)-1,3-oxazol-2-yl]-5-methylpyridin-2-yl}acetamide (Compound I-50) (0.028 g, 12%). LCMS (FA): m/z=404.6 (M+H).